StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Stock analysts at StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of Bellerophon Therapeutics stock opened at $0.06 on Friday. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.10. The business’s 50 day simple moving average is $0.04 and its two-hundred day simple moving average is $0.05. The stock has a market capitalization of $672,650.00, a P/E ratio of -0.07 and a beta of 0.71.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.